Suspended
Tucatinib Application for HER2+ Metastatic Breast Cancer
What is being tested
Data Collection
Who is eligible
Brain Diseases+9
+ Brain Neoplasms
+ Breast Diseases
How is it accessible
Suspended
Available upon a request by a licensed MDExpanded Access
Summary
Principal SponsorSeagen Inc.
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
This study focuses on the use of a drug called Tucatinib for individuals diagnosed with HER2+ Metastatic Breast Cancer. HER2+ is a type of breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). The study aims to provide access to Tucatinib for patients who are not part of other clinical trials. The importance of this study lies in its potential to offer a new treatment option for patients with this specific type of breast cancer.
Official TitleExpanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Principal SponsorSeagen Inc.
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Conditions
Pathology
Brain DiseasesBrain NeoplasmsBreast DiseasesBreast NeoplasmsCentral Nervous System DiseasesNeoplasmsNeoplasms by SiteNervous System DiseasesNervous System NeoplasmsSkin DiseasesCentral Nervous System NeoplasmsSkin and Connective Tissue Diseases
Criteria
Inclusion Criteria: \- Exclusion Criteria: \-
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has no location dataSave this study to your profile to know when the location data is available.
SuspendedNo study centers